Short answer
Tyra Biosciences, Inc. (TYRA) filed its Q1 2026 10-Q quarterly report on May 13, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$39M
- −39.6% YoY
- EPS (diluted)
- −$0.64
- −36.2% YoY
Source: XBRL data from the Tyra Biosciences, Inc. (TYRA) Q1 2026 10-Q on SEC EDGAR. USD.
Tyra Biosciences, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No risk-factors section provided in the submitted text
- New insider trading plans adopted by CEO, CFO, and finance VP during quarter
- Plans authorize potential sales of 256,975 shares through 2027
- No unregistered equity sales or issuer repurchases during quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tyra Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.